Intestinal research
Cure8 research brief
Why This Matters
This study describes use of upadacitinib for children and young adults with highly refractory IBD and reports that most patients stayed on therapy at 1 year; a small subgroup treated with combined upadacitinib and vedolizumab achieved remission and avoided surgery in most cases.
That could matter to families and clinicians facing few options after multiple treatment failures.
Who Should Pay Attention
Pediatric patients with refractory IBD, parents and caregivers of children with difficult-to-treat IBD, pediatric gastroenterologists, and clinicians managing patients after multiple biologic/JAK failures.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This retrospective single-center abstract reports outcomes of upadacitinib in 18 patients with highly refractory pediatric-onset IBD (including Crohn’s and UC) and describes 5 cases given combined upadacitinib+vedolizumab therapy (UVCT).
The study’s primary outcome was drug continuation; secondary outcomes included steroid- and tacrolimus-free remission, safety, and endoscopic improvement. At 52 weeks the continuation rate was 55.6%. Among five UVCT patients, four achieved clinical remission and three had endoscopic improvement; one very early-onset IBD patient required colectomy.
The report is a small, retrospective series from a single center covering Nov 2022–Nov 2025. It suggests upadacitinib can be effective and that adding vedolizumab as a salvage combination may help avoid surgery in select, highly refractory pediatric cases. The data are preliminary and limited by small numbers and study design.
If you’re a caregiver or clinician treating pediatric-onset, treatment-refractory IBD, this study is a signal that upadacitinib — and in a few cases combining it with vedolizumab — has been used successfully in a small series, but larger prospective studies are needed to establish safety and best use.
Keep In Mind
This is a small, retrospective, single-center study (n=18) with short follow-up and potential selection bias. Findings are hypothesis-generating; the authors call for prospective, multicenter studies to define optimal use. Combination therapy here was reported in five patients only. SummaryConfidence is medium.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationIntestinal research
AuthorsHirotaka Shimizu, Ichiro Takeuchi, Hiroshi Oue +4 more
InstitutionCenter for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan. shimizu-h@ncchd.go.jp.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 6, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Dual biologic therapy in inflammatory bowel disease, a retrospective cohort study of vedolizumab and anti-tumor necrosis factor alpha therapy in children.
This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...
Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...